These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1860657)

  • 1. [Estrogen substitution therapy in climacteric: should progesterone be omitted in hysterectomized women?].
    Huber J
    Geburtshilfe Frauenheilkd; 1991 Apr; 51(4):257-61. PubMed ID: 1860657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Differentiated therapy of the climacteric syndrome].
    Huber J
    Wien Med Wochenschr; 1992; 142(5-6):124-6. PubMed ID: 1615681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hormonal contraception and substitution therapy: the importance of progestogen for cardiovascular diseases].
    Kuhl H
    Geburtshilfe Frauenheilkd; 1992 Nov; 52(11):653-62. PubMed ID: 1452000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of hormone substitution therapy on AT III in women in the climacteric].
    Enzelsberger H; Heytmanek H; Kurz C; Metka M
    Zentralbl Gynakol; 1991; 113(11):639-44. PubMed ID: 1656654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hormone treatment in the climacteric].
    Siegberg R; Pekonen F
    Nord Med; 1993; 108(10):259-62. PubMed ID: 8414944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of combined conjugated estrogen-medrogestone replacement therapy on lipid profiles, climacteric symptoms and the endometrium].
    Belaisch J; Nappi C; Affinito P; De Gezelle H; Botelho M; Oliveira HM; Martinez-Oliveira J; Gonzaga F
    J Gynecol Obstet Biol Reprod (Paris); 2000 Feb; 29(1):29-40. PubMed ID: 10675831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hormone substitution in menopause].
    Keller PJ; Maurer-Major E
    Praxis (Bern 1994); 1997 Sep; 86(38):1458-62. PubMed ID: 9381046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatic changes in different hormone replacement therapies in climacteric].
    Foth D; Römer T; Panzig E
    Zentralbl Gynakol; 1995; 117(7):349-52. PubMed ID: 7668064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M; Simoncini T; Fuller S; Genazzani AR
    Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic features of menopausal and postmenopausal applicants for life insurance.
    Schiefeling M
    J Insur Med; 1996; 28(1):27-34. PubMed ID: 10172866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hormone substitution in climacteric. Position of the German Menopause Society].
    Schneider HP; Kuhl H; Dören M; Hesch D
    Zentralbl Gynakol; 1995; 117(6):B1-4. PubMed ID: 7645352
    [No Abstract]   [Full Text] [Related]  

  • 12. [Principles of hormone substitution in the postmenopause period].
    Keller PJ
    Schweiz Rundsch Med Prax; 1991 Apr; 80(16):431-4. PubMed ID: 2038641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the climacteric symptomatology modifications and clinical-instrumental parameters in women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and in surgical menopause treated with estrogen replacement therapy. Part I].
    Savoca S; D'Agosta S; Lombardo G
    Minerva Ginecol; 2007 Jun; 59(3):205-14. PubMed ID: 17576399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
    Skouby SO; Al-Azzawi F; Barlow D; Calaf-Alsina Erdogan Ertüngealp J; Gompel A; Graziottin A; Hudita D; Pines A; Rozenberg S; Samsioe G; Stevenson JC;
    Maturitas; 2005 May; 51(1):8-14. PubMed ID: 15883103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
    Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormone substitution in climacteric and postmenopause. Consensus report of the Austrian Menopause Society].
    Metka M; Heytmanek G; Enzelsberger H; Kurz C; Huber J; Brandstätter N; Tscherne G; Tabarelli M; Holzer G
    Wien Med Wochenschr; 1992; 142(5-6):94-5. PubMed ID: 1615684
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of estrogen replacement therapy on lipids. Implications for cardiovascular risk.
    LaRosa JC
    J Reprod Med; 1985 Oct; 30(10 Suppl):811-3. PubMed ID: 4078813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study.
    Bouaziz E; Canonico M; Verstuyft C; Carcaillon L; Martin F; Scarabin PY; Guiochon-Mantel A;
    Maturitas; 2009 Oct; 64(2):136-8. PubMed ID: 19782484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.